Discover a new way to find and share stories you'll loveā€¦ Learn about Reading Desk

Blog Profile / In the Pipeline


URL :http://pipeline.corante.com/
Filed Under:Medical / Pharmaceutical
Posts on Regator:1972
Posts / Week:9.3
Archived Since:November 3, 2010

Blog Post Archive

Try Some Reactions. Actually, Try Them All.

Here's a really nice example of high-throughput reaction discovery/condition scouting from a team at Merck. They certainly state the problem correctly: Modern organic synthesis and especially transition metal catalysis is redefiningShow More Summary

Holiday Blogging

I'm doing research today and tomorrow, but after that I'll be taking the rest of the week off, so blogging will be intermittent. Wednesday I'll be home making the traditional chocolate pecan pie (recipe here, with many helpful suggestions in the comment section), along with some of the other Thanksgiving food that can be prepared ahead of time. Show More Summary

Reaction Discovery Reviewed

I've written several times here about reaction discovery techniques, going back to 2011. And I've been meaning to link to this recent review in Nature Chemistry, because it's an excellent summary of the field and the relevant literature. Show More Summary

Deadly Incompetence in India

Here, then, is the bottom of the drug-manufacturing barrel: the recent case in India where women at a sterilization clinic were poisoned by defective ciprofloxacin tablets. They were supposed to be getting 500mg of the antibiotic, but...Show More Summary

The Cost of Developing A New Drug

The Tufts Center for the Study of Drug Development has a new estimate for the cost of developing a new drug. Past estimates have been greeted with a range of reactions, not all of them favorable. In general, people who actually do drug...Show More Summary

Virtual Covalent Screening

Covalent drugs have been a big item in R&D over the last few years, and I wrote here about covalent fragments. The whole topic of reactive groups in small molecules and their interaction with living systems and biomolecules is a complicated...Show More Summary

Amgen Claims It All

There's plenty of excitement about PCSK9, the latest LDL-lowering pathway to make it deep into the clinic. You can tell that companies (and investors) have high hopes for it, since it's heading right into a market that's dominated by generic statins. Show More Summary

More From The Bottom of the Publishing Barrel

Now, if you want to get a paper published in a prestigious journal like The International Journal of Advanced Computer Technology, you'd better make sure that you're up to it. You'd better make sure that you have good stuff to report, and that the paper is worth a spot in a venue like that. Show More Summary

Sanofi Beats the Drum

We saw AstraZeneca talking about its upcoming onslaught of drug approvals the other day, and not to be outdone, Sanofi is doing the same. Actually, they're seeing AstraZeneca's puny bet and raising them: Sanofi says that they could have...Show More Summary

Bind's Attempts To Remake Chemotherapy

There's a lot of effort (and a lot of money) going into targeted nanoparticle drug delivery. And that's completely understandable, because the way we dose things now, with any luck, will eventually come to seem primitive. So you used...Show More Summary

Dear Practitioner, You Say?

Spam mail is evolving: this afternoon I had one purportedly from the American Medical Association, although it was definitely not sent from their domain. In slightly ungrammatical English (but a cut above many other spammers), it informs me that they're sharing a document with me on Google Docs, and invite me to click a link. Show More Summary

AstraZeneca: How Many Approvals, Again?

So AstraZeneca says that they're expecting "8 to 10 " approvals in 2015-2016. Has anyone ever done that? Even close? I take it that this whole press release is there to pump up investors and keep Pfizer from coming back and making another bid for them, but although the company does have a lot of stuff going on, this just seems wildly optimistic. Show More Summary

Wait, We Didn't Tell You About That Endpoint?

Hmm. Via Twitter, we find this interesting example of moving the goalposts. NeoStem, a small stem-cell company, announced results the other day for a trial of their cardiac stem cell therapy. One bearish trader who'd been following them...Show More Summary

TMS Azide Explosions

There's been a lot of safety on the blog this week. One recent accident I haven't talked about is an azide explosion at Minnesota - C&E News, though, has plenty of coverage. Back in June, a grad student was injured when a batch of trimethylsilyl azide exploded - a 200 gram batch. Show More Summary

Chemical Myths

Several folks on my Twitter feed have mentioned a new book coming out from Springer, 100 Chemical Myths. I haven't seen a copy, but it's supposed to "deals with popular yet largely untrue misconceptions and misunderstandings relatedShow More Summary

How Not to Do It: NMR Magnets

Here's an NMR imaging blog with details of a recent problem in an Indian facility. Two people ended up stuck to the machine, pinned by an oxygen cylinder (!) that one of them brought into the room. Both sustained injuries. There areShow More Summary

Allergan Escapes Valeant

The Allergan / Valeant saga has come to an end, with Allergan fighting them off by doing a deal to be taken over by Actavis. No word yet on whether they'are going to let Allergan keep the invisible golf course. Valeant is, of course,...Show More Summary

Vytorin Actually Works

The data from the IMPROVE-IT trial on cardiovascular outcomes for Vytorin have been released. And the combination met the primary endpoint: fewer heart attacks and strokes compared to those already on statin therapy alone. Matthew Herper has an excellent roundup of the results and their context. Show More Summary

Fatalities at DuPont

As many readers will have heard, there was a fatal accident at a DuPont plant in the Houston area over the weekend. Four workers were killed by methyl mercaptan (methanethiol), and here's more on what happened. As is often the case,Show More Summary

The New York TImes on Drug Discovery

The New York Times Magazine has a piece on the current problems with drug discovery. I was interviewed by the author, and get I quoted at one point. Nothing in the article will amaze any regular reader here, but it's probably the first...Show More Summary

Copyright © 2011 Regator, LLC